Turkey Fusion Biopsy Market Size & Outlook, 2026-2034
Turkey Fusion Biopsy Market Insights
- Based on Reed Intelligence findings, the Turkey Fusion Biopsy Market reached USD 13.1 Million in 2025 and is estimated to attain USD 31.39 Million by 2034.
- From 2026 to 2034, the Turkey market is expected to grow at a steady CAGR of 10.31%.
- Within the By Type category, MRI-Ultrasound Fusion Biopsy dominated in 2025 in terms of market size contribution.
- Over the forecast period, Transperineal Fusion Biopsy is forecasted to deliver the fastest growth, positioning it as the most lucrative By Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Turkey accounted for 0.72% of the global Fusion Biopsy Market size.
- By 2034, United States is expected to lead the global Fusion Biopsy Market in terms of market size.
- Within Middle East and Africa, United Arab Emirates is projected to dominate the regional Fusion Biopsy Market size by 2034.
- Turkey is identified as the fastest-growing market in Middle East and Africa, anticipated to reach USD 31.68 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 13.1 Million |
| Market Size In 2034 | USD 31.39 Million |
| Largest segment | MRI-Ultrasound Fusion Biopsy |
| Units | Revenue in USD Million |
| CAGR | 10.31% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Application |
|
| By End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Turkey Fusion Biopsy Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI-Ultrasound Fusion Biopsy | XX.x | XX.x | XX.x | 6.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cognitive Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Transperineal Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Turkey Fusion Biopsy Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostate Cancer Diagnosis | XX.x | XX.x | XX.x | 5.9 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Focal Therapy Planning | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Active Surveillance Monitoring | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Turkey Fusion Biopsy Market By End Use 2026-2034 (USD Million)
| By End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 7.1 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Imaging Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
